Cara Therapeutics Announces Presentations at Kidney Week 2019
November 01 2019 - 7:00AM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus by selectively targeting peripheral
kappa opioid receptors, today announced a late-breaking oral
presentation and two posters on KORSUVA™ (CR845/difelikefalin)
Injection will be presented at Kidney Week 2019, the American
Society of Nephrology’s Annual Meeting, to be held November 5-10,
2019, in Washington, DC.
The late-breaking oral presentation will include data from
KALM-1, the pivotal Phase 3 clinical trial of KORSUVA Injection in
hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP), and the posters will include
data from the Phase 2 trial of KORSUVA Injection in the same
patient population. KORSUVA Injection is Cara’s first-in-class drug
candidate designed to target kappa opioid receptors in the body’s
peripheral nervous system, as well as certain immune cells.
Details for the presentations are as follows:
Late-Breaking Oral
Presentation:Title: Efficacy and Safety
of Difelikefalin in Patients Undergoing Hemodialysis With Pruritus:
Results From a Phase 3 Randomized, Controlled Study
(KALM-1)Abstract Number: FR-OR134Date /
Time: Friday, November 8, 2:45 to 3 p.m.
ETPresenter: Steven Fishbane, MD, Department of
Medicine, Donald and Barbara Zucker School of Medicine at
Hofstra/Northwell, Great Neck, NY
Poster Presentations: Title:
Difelikefalin Improved Quality of Life (5-D Itch Scale-Domains) in
Hemodialysis Patients With Pruritus in an 8-Week Phase 2
Randomized, Placebo-Controlled StudyPoster Number:
TH-PO245Date / Time: Thursday, November 7, 10 a.m.
to 12 p.m. Presenter: Robert Spencer, Cara
Therapeutics
Title: Difelikefalin Significantly Reduced
Sleep Disturbance in Hemodialysis Patients With Moderate-to-Severe
Pruritus in an 8-Week Phase 2, Randomized, Placebo-Controlled
StudyPoster Number: TH-PO247Date /
Time: Thursday, November 7, 10 a.m. to 12 p.m.
ETPresenter: Sarbani Bhaduri, MD, Cara
Therapeutics
For more information about Kidney Week 2019, visit
https://www.asn-online.org/education/kidneyweek/.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors (KORs). Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body's peripheral nervous system, as well as
certain immune cells. In both Phase 3 and Phase 2 trials, KORSUVA
Injection has demonstrated statistically significant reductions in
itch intensity and concomitant improvement in quality of life
measures in hemodialysis patients with moderate-to-severe chronic
kidney disease-associated pruritus (CKD-aP). KORSUVA Injection is
currently being investigated in pivotal Phase 3 trials in
hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2
trials for the treatment of pruritus in patients with CKD, atopic
dermatitis and primary biliary cholangitis (PBC).
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
MEDIA CONTACT: Annie Starr 6 Degrees
973-415-8838 astarr@6degreespr.com
INVESTOR CONTACT: Jane Urheim Stern Investor
Relations, Inc. 212-362-1200 Jane.Urheim@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024